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Introduction {#sec005}
============

Cystatin C (cysC) is an endogenous protease inhibitor (Molecular weight \~ 13.4 kDa) produced at a constant rate in all nucleated cells\[[@pone.0178796.ref001]\]. It is freely filtered and thus the plasma concentration of cysC is dependent on the glomerular filtration rate (GFR) and cysC production rate. In healthy individuals essentially no cysC is excreted in the urine \[[@pone.0178796.ref002]\] due to effective reabsorption and degradation of filtered cysC in the proximal tubule (PT) \[[@pone.0178796.ref003]\]. Urinary cysC excretion (U-cysC) has been studied as a marker of kidney injury, most likely reflecting tubular dysfunction \[[@pone.0178796.ref004]\]. Proximal tubule (PT) disorder, such as tenofovir induced tubular dysfunction, has been associated with an increased U-cysC \[[@pone.0178796.ref005]\]. U-cysC predicts the development of acute kidney injury (AKI) \[[@pone.0178796.ref006]\] and subsequent renal failure \[[@pone.0178796.ref007]\]. In renal transplantation, levels of U-cysC, as early as 6 hours post-operative, are associated with late graft function \[[@pone.0178796.ref008]\]. In chronic kidney disease (CKD) U-cysC correlates with GFR, and it has been demonstrated that patients with GFR \< 30 mL/min have a higher U-cysC excretion when compared to patients with GFR \> 70 mL/min \[[@pone.0178796.ref009], [@pone.0178796.ref010]\]. In a diabetic rat model increased U-cysC preceded and predicted the development of diabetic nephropathy \[[@pone.0178796.ref011]\] and in humans with diabetes increased U-cysC was associated with a greater risk of declining eGFR \[[@pone.0178796.ref012]\]. This suggests that U-cysC, as a marker of early tubular dysfunction, may precede the decline in GFR, and serve as a marker of progression in CKD.

The multi-ligand endocytic receptors megalin and cubilin are heavily expressed in the PT brush border membrane and essential for the reabsorption of a large number of filtered proteins in the PT \[[@pone.0178796.ref013]--[@pone.0178796.ref015]\]. Endocytosis of cubilin and cubilin ligands in the PT is dependent on the interaction with megalin \[[@pone.0178796.ref016]\] and the two proteins act in concert to mediate tubular recovery of a number of established urinary biomarkers such as albumin, vitamin D-binding protein (DBP), retinol binding protein (RBP), alpha-1-microglobulin, and neutrophil gelatinase-associated lipocalin (NGAL) \[[@pone.0178796.ref017]--[@pone.0178796.ref022]\]. Injected exogenous cysC binds to megalin and is reabsorbed by a megalin dependent process in the PT \[[@pone.0178796.ref023]\]; however, the molecular mechanisms regulating the reabsorption of endogenous cysC have not been fully characterized, and while it has been hypothesized that in both AKI and CKD the increased urinary excretion of cysC (and other biomarkers) is due to decreased reabsorption of cysC in the PT \[[@pone.0178796.ref024]\], the exact mechanism and role of megalin and cubilin has not been fully characterized.

To study the importance of megalin and cubilin for the normal tubular reabsorption of endogenous cysC, we analyzed the *in vitro* binding of cysC to these receptors and examined renal handling of cysC *in vivo* in mice with conditional kidney specific knockout of the megalin and/or cubilin genes. To further characterize the mechanism of increased U-cysC in AKI we evaluated the effect of ischemia/reperfusion (I/R) injury in rats on megalin expression, U-cysC, and tubular cysC uptake.

Materials and methods {#sec006}
=====================

Materials {#sec007}
---------

Affinity purified human cysC was purchased from BioVender R&D (Brno, Czech Republic) Cat. No: RD172009100. Primary polyclonal goat anti-mouse cysC antibodies were obtained from R&D Systems (Abingdon, United Kingdom) catalog number AF1238. Primary polyclonal rabbit anti mouse megalin antibody was a gift from E. de Heer, Dept. of pathology, at University of Leiden (Leiden, Holland). Primary polyclonal rabbit anti mouse cubilin antibody was obtained from P. Verroust, INSERM U64 (Paris, France). The secondary antibodies included Alexa Fluor® 488 donkey anti-rabbit IgG and Alexa Fluor® 568 donkey anti-goat IgG (Thermo Fisher Scientific inc., Waltham, USA). Rat U-cysC and mouse plasma cysC were measured by ELISA as specified by the supplier (Quantikine® ELISA, R&D Systems (Abingdon, United Kingdom), Cat. No. MSCTC0).

Animal models {#sec008}
-------------

All animal experiments were performed in accordance with provisions for the animal care licenses provided by the Danish National Animal Experiments Inspectorate, and approved by the ethics comity of the Danish National Animal Experiments Inspectorate. All animals had free access to a standard rodent diet and water, and were kept in a 12:12 hour light-dark cycle. Urine was collected for 24 hours in metabolic cages. Rats used for perfusion fixation were sacrificed by intra peritoneal pentobarbital injection. Remaining rats were sacrificed by cervical dislocation at end of study. Mice used for preparation of sections were anesthetized by isoflouran, and perfusion-fixed while unconscious--the remainder of the mice were returned to their original cages.

### Megalin and/or cubilin deficient mice {#sec009}

Cub ^-/-^/meg^-/-^ mice as well as cub ^-/-^ mice under control of the Wnt4 promoter were produced as previously described \[[@pone.0178796.ref025]\]. These mice have approx. 90% reduction in kidney PT megalin or cubilin expression \[[@pone.0178796.ref025]\]. Wildtype mice on a similar, mixed 129/C57 background were used as controls. Kidneys from 9 mice (3 cub ^-/-^ mice, 3 cub ^-/-^/meg^-/-^ mice, and 3 wildtype) were fixed by retrograde perfusion through the abdominal aorta with 2% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4 for paraffin embedding and immunohistochemistry.

Urine was collected from 12 mice (4 cub ^-/-^ mice, 4 cub ^-/-^/meg^-/-^mice and 4 wildtype mice ranging from 55 to 106 weeks of age). 12 plasma samples (4 cub ^-/-^ mice, 4 cub ^-/-^/meg^-/-^mice and 4 wildtype mice) collected in another study were used to compare plasma cysC levels in the 3 phenotypes.

### Unilateral nephrectomy followed by I/R injury in rats {#sec010}

Thirty-nine male, Wistar rats with a starting weight of 230--250 g were included in the study (16 sham operated and 23 I/R operated). All surgery was performed through an abdominal incision under anesthesia with sevoflurane. Animals were placed on a heating pad to maintain a rectal temperature of approx. 36°C. At onset of surgery and every 8 to12 hours for the first 24 hours after surgery, rats were injected with buprenorphine, 0.05 mg/kg subcutaneously (SC) after which buprenorphine (0.3 mg/ml) was supplied in the drinking water for 48 hours for post-operative pain relieve. Rats were allowed recovery from anesthesia before being returned to the cages.

The right kidney was removed 7 (+/- 1) days prior to I/R injury. I/R injury was induced, by clamping of the left renal artery for 37 minutes using a non-traumatic clamp, after which the clamp was removed. The obstruction of blood flow as well as reperfusion was confirmed by color changes of the kidney. To avoid arterial spasm lidocaine was applied to the artery around the clamp prior to removal. The sham-operated controls underwent same procedure except for the arterial clamping. During nephrectomy and I/R surgery, rats were injected SC with 4 mL of isotonic saline. This was repeated day 1 after surgery. Twenty-four hour urine samples (n = 31) were collected 1 day prior to as well as two and six days after I/R or sham operation. Eight rats, 4 sham and 4 I/R operated, were sacrificed at day 3 after surgery for perfusion fixation of the left kidney as described earlier.

Surface plasmon resonance analysis {#sec011}
----------------------------------

Human cysC was dissolved in running buffer (CaHBS: 10 mM HEPES, 150 mM NaCl, 1.5 mM CaCl2, 1 mM EGTA, pH 7.4) at 7 different concentrations (20 nM, 50 nM, 100 nM, 200 nM, 300 nM, 400 nM and 500 nM) and analyzed for binding to purified, immobilized rat megalin and cubilin \[[@pone.0178796.ref026]\] on a Biacore® 3000 surface plasmon resonance apparatus (GE healthcare, Pittsburgh, USA). In order to specifically inhibit cysC binding to megalin and cubilin the chip was pre-saturated with receptor associated protein (RAP) (5 μM), a well-known inhibitor of ligand binding to megalin. To identify calcium dependent binding 20 mM of EDTA was added to the running buffer with cysC at a concentration of 150 and 300 nM, respectively. Kinetic parameters were determined by BIAevaluation 4.1 software (GE healthcare, Pittsburgh, USA) using a Langmuir 1:1 binding-model and global fitting.

Immunoblotting {#sec012}
--------------

Two μL of urine sample, diluted according to urine output, were mixed with 4X Laemmli buffer, heated to 95°C for 5 min, loaded onto a 16% gel, and separated by standard SDS-PAGE. Kaleidoscope™ Precision Plus Protein™ Standards (Hercules, USA) was used as size marker. Protein was transferred to polyvinylidene difluoride membrane using the iBlotTM Dry Blotting System (Invitrogen, Thermo Fisher Scientific inc., Waltham, USA), fixed with Odyssey® (LI-COR, Inc., Lincoln, USA) blocking buffer (BB) diluted 1:1 with 0.1 M phosphate buffered saline (PBS), then incubated with 6 mL goat anti-mouse cysC antibody (0.1 μg/mL) in 1:1 BB/PBS (0.1 M) solution and left overnight at 4°C. Following wash the membranes were incubated for 1 hour with the relevant secondary antibody in PBS. Proteins were detected using OdysseyTM infrared imager (LI-COR, Inc., Lincoln,USA).

Immunohistochemistry {#sec013}
--------------------

Kidney tissue was fixed as described earlier, dehydrated and embedded in paraffin. For visualization of cysC, megalin, and cubilin in the kidney cortex, 2 μm paraffin sections were cut and rehydrated using standard methods. Sections were labeled using anti megalin (1:400/1:800), anti cysC (1:60), and/or anti cubilin (1:4000) primary antibodies over night at 4°C followed by incubation with relevant secondary antibodies for 60 minutes at room temperature. 0.01 M PBS containing 0.1% bovine serum albumin, 0.3% Triton X-100 adjusted to pH 7.4 was used for antibody dilution. Control labeling experiments involved incubation with no primary antibody or each of the three primary antibodies individually followed by the secondary antibodies. No cross reactivity or unspecific secondary binding was detected. Images were recorded using a Leica TCS SL Spectral Confocal Microscope (TM Leica Microsystems, Wetzlar, Germany).

Statistical analysis {#sec014}
--------------------

Normal distribution of data was obtained after transformation to a log10 scale and normality was confirmed using qq-plots and histograms. Paired and unpaired students t-test was used when appropriate to compare data. A p-value \< 0.05 was considered significant. The STATA 12.1 (StataCorp LP, College Station, USA) software was used for analysis.

Results {#sec015}
=======

CysC binds both to purified megalin and cubilin {#sec016}
-----------------------------------------------

Surface plasmon resonance analysis revealed a high affinity binding of cysC to megalin (Kd \~ 32 nM) and cubilin (Kd \~ 24 nM). Receptor associated protein (RAP), a known inhibitor of ligand binding to megalin, inhibited cysC binding to megalin and cubilin completely ([Fig 1](#pone.0178796.g001){ref-type="fig"}). The addition of 20 mM EDTA did not inhibit cysC binding to megalin or cubilin (data not shown).

![Cystatin C binding to megalin and cubilin in surface plasmon analysis.\
Surface plasmon resonance analysis showing binding of purified human cysC to immobilized megalin (A) and cubilin (B) at dilutions ranging from 20 nM to 500 nM. The calculated Kd was approximately 32 nM for binding to megalin and 24 nM for binding to cubilin. In (C) and (D) the flow of cystatin C (150 nM) was preceded by binding of RAP (5 μM) essentially abolishing the binding to megalin (C) and cubilin (D).](pone.0178796.g001){#pone.0178796.g001}

U-cysC excretion is increased in megalin/cubilin deficient mice and associated with decreased proximal tubule uptake {#sec017}
--------------------------------------------------------------------------------------------------------------------

Urinary excretion of cysC was identified as a single, approximately 13 kDa band in urine samples from cub ^-/-^/meg^-/-^ mice, but not cub ^-/-^ or wildtype mice ([Fig 2](#pone.0178796.g002){ref-type="fig"}).

![Urinary cystatin C excretion in mice.\
Western blot of urine samples, showing the presence of cysC in urine from cub ^-/-^/meg^-/-^ mice (lanes 1--4), cub ^-/-^ mice (lanes 5--8), and wildtype mice (lanes 9--12). CysC was identified in the urine from cub ^-/-^/meg^-/-^ mice only. The urines were loaded on the gel according to excretion rate.](pone.0178796.g002){#pone.0178796.g002}

Immunohistochemistry revealed no uptake of cysC in megalin deficient PT cells (indicated by arrow in [Fig 3C](#pone.0178796.g003){ref-type="fig"}). A mosaic expression of megalin is noted in the PT of cub ^-/-^/meg^-/-^ mice with a few tubular profiles revealing residual expression of megalin ([Fig 3C and 3D](#pone.0178796.g003){ref-type="fig"}). These cells do show labeling for endogenous cysC ([Fig 3D](#pone.0178796.g003){ref-type="fig"}) and serve as an internal control. We observed vesicular labeling for cysC in wildtype PT cells consistent with endocytic uptake of filtered, endogenous cysC ([Fig 3E and 3F](#pone.0178796.g003){ref-type="fig"}). Similar labeling was observed in cubilin deficient cells ([Fig 3G and 3H](#pone.0178796.g003){ref-type="fig"}). Mean plasma levels of cysC were significantly higher in cub ^-/-^/meg^-/-^ -mice (620 (791; 472) ng/mL) than in cub ^-/-^ (457 (633; 315) ng/mL) and wildtype mice (433 (560; 326) ng/mL).

![Renal cortical sections from mice.\
Immunohistochemistry was used to identify megalin, cubilin, and cysC in kidney cortical sections from wildtype (A, E and F), cub ^-/-^ (G and H) and cub ^-/-^/meg^-/-^ mice (B, C and D). In proximal tubule brush border of wildtype mice the expression of cubilin (green A) and megalin (green B) co-localized with vesicular accumulation of cysC (red A and B). In Cub ^-/-^ mouse the labeling for cysC appeared similar to wildtype despite the absence of immuno-detectable cubilin (G). Megalin labeling appeared normal in Cub ^-/-^ (H). Note that megalin is also expressed in proximal tubule cells forming part of Bowman's capsule with corresponding cysC uptake (arrows in H). In cub^-/-^/meg^-/-^ mouse residual expression of megalin was observed only in a few mosaic tubular profiles (B and C (arrows indicating proximal tubules not expressing megalin)) when compared to wildtype (F) illustrating the high degree of conditional knockout. Uptake of cysC was observed only in the few proximal tubular cells with residual megalin expression selected in (C and D). Note that cells not expressing megalin do not reveal any cysC uptake (arrows in D). Scalebars in sections A, C, D, G and H correspond to 50 μm and scalebars in sections A and B correspond to 200 μm.](pone.0178796.g003){#pone.0178796.g003}

U-CysC excretion is increased following I/R injury in rats, but is not associated with reduced megalin expression {#sec018}
-----------------------------------------------------------------------------------------------------------------

A significant increase in U-cysC excretion was observed in rats exposed to I/R injury two days after the intervention when compared to baseline. A significant decrease of U-cysC in the sham group was observed at day six, when compared to baseline. U-cysC levels in I/R injury exposed rats, was significantly different (higher) from sham group at day two and six ([Table 1](#pone.0178796.t001){ref-type="table"}).

10.1371/journal.pone.0178796.t001

###### U-cysC excretion after I/R injury vs sham rats.

![](pone.0178796.t001){#pone.0178796.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------
             Baseline   2 days post op.   6 days post op.                                                                               
  ---------- ---------- ----------------- ----------------- ---- ----------------------------- ---------- ---- ------------------------ ---------
  **Sham**   8          78                73; 83            12   78                            51; 83     6    66\#\                    62; 69
                                                                                                               ^(\#p\ =\ 0,03)^         

  **I/R**    18         91                64; 120           19   288\*\# ^(\*\#p\ =\ 0.000)^   161; 884   10   143\* ^(\*p\ =\ 0.04)^   94; 170
  -----------------------------------------------------------------------------------------------------------------------------------------------

Rat U-cysC at baseline, two and six days after I/R injury or sham operation.

Significant differences from sham are marked with \* (unpaired t-test).

Significant differences from baseline are marked with \# (paired t-test).

Cystatin C excretion rates are given in microgram/day/kg rat.

In rats subjected to I/R injury morphological evidence of PT cell injury was evident. We observed cell detachment from the basal membrane, tubular dilation, and morphologic signs of acute tubular necrosis with interstitial hyper-cellularity, but also chromatin accumulation as sign of cell protein synthesis and cell regeneration ([Fig 4A](#pone.0178796.g004){ref-type="fig"}). Immunohistochemistry revealed reduced vesicular labeling for cysC in the I/R treated rats despite preserved expression of megalin in most PT cells ([Fig 4B](#pone.0178796.g004){ref-type="fig"}). This could suggest decreased turnover of endocytic vesicles, not reduced megalin expression *per se*, as the cause of increased U-cysC excretion in this model. In sham operated rats we observed a normal vesicular labeling for cysC co-localizing with megalin expressing PT cells, consistent with endocytic uptake of filtered, endogenous cysC ([Fig 4C](#pone.0178796.g004){ref-type="fig"}). Cubilin staining followed the same pattern as megalin (not shown).

![Renal cortical sections of rats exposed to I/R injury.\
HE stain of a cortical kidney section from I/R exposed rat (4A). Sham operated rat section is shown as insert in right corner for comparison. Evidence of acute tubular injury can be observed, consisting of tubular luminal distension (\*), irregular nuclear size (\#), interstitial inflammation (x) and loss of tubular cell adhesion to the basal membrane (arrow). Immunohistochemistry identified megalin (green) and cysC (red) in kidney cortical sections from rats two days after I/R injury (4B) or sham operation (4C). Normal, endocytic uptake of cysC was observed in most megalin expressing cells in sham operated rats (4C). In I/R operated rats, a clearly reduced, intracellular labeling for cysC was observed indicating a reduced endocytic uptake (4B), despite preserved expression of megalin in the proximal tubule brush border, Megalin, but not cysC, was identified in tubules with evidence of proximal tubule cell injury as indicated by \*(4D). Scalebar = 50 μm.](pone.0178796.g004){#pone.0178796.g004}

Discussion {#sec019}
==========

This study demonstrates that the multi-ligand, endocytic receptor megalin is essential for the normal PT recovery of filtered, endogenous cysC. It also demonstrates that increased U-cysC excretion, as a marker of PT I/R injury, is the result of defective PT receptor mediated endocytosis, not reduced megalin expression in the PT. This is based on the following observations: 1) Megalin binds cysC with high affinity, which can be inhibited by RAP, 2) increased urinary excretion of endogenous cysC in megalin deficient mice is associated with abolished endocytic uptake in the PT cells, 3) U-cysC increases significantly following I/R injury, and finally 4) PT uptake of cysC, as reflected by an intracellular, vesicular labeling, is decreased in cells with evidence of injury despite the preserved expression of megalin.

The binding of cysC to megalin is consistent with findings of Kaseda et al. who examined renal handling of injected, exogenous cysC \[[@pone.0178796.ref023]\]. We observed an additional binding of cysC to cubilin; however, this binding did not appear to be essential for urinary excretion or tubular uptake as demonstrated by the normal tubular cysC handling in cubilin deficient mice. Similar binding characteristics have been demonstrated for other filtered megalin and cubilin ligands. Nykjaer et al. showed that DBP binds with strong affinity to megalin and cubilin when examined by surface plasmon resonance \[[@pone.0178796.ref027]\]; however, when urinary excretion of DBP was examined using cubilin deficient mice it was independent of cubilin \[[@pone.0178796.ref017]\]. In humans, evidence suggests that the reabsorption of DBP may at least in part depend on cubilin. Albumin also binds to both megalin \[[@pone.0178796.ref028]\] and cubilin. Unlike cysC, cubilin deficient mice reveal albuminuria even in the presence of functional megalin \[[@pone.0178796.ref025]\] probably due to the much higher affinity of albumin binding to cubilin when compared to megalin. In the absence of both megalin and cubilin the urinary excretion of albumin increases further \[[@pone.0178796.ref025]\] demonstrating the significance of the cubilin-megalin interaction. In this study, plasma levels of cysC observed in the double KO mice were significantly higher than the observed plasma cysC levels in the cubilin KO and the wildtype mice. This could be due to a decreased number of functional nephrons in the double KO mouse model, caused by the absence of megalin during nephro-genesis or podocyte function as suggested by Nielsen et al \[[@pone.0178796.ref029]\]. If this is the case, the total amount of cysC filtered, per nephron, in the double KO mice in steady state is higher than in the cubilin KO and wildtype mice. This increased per nephron cysC load in the double KO mice may contribute to the increased urinary excretion of cysC observed in the double KO mice. Never the less, we believe the total absence of cysC endocytosis in tubular cells not expressing megalin, to be the primary cause of the increased urinary cysC excretion in megalin KO mice, as observed in this study.

Ligand binding to megalin and cubilin is believed to be Ca^2+^-dependent, which has been demonstrated with many different ligands \[[@pone.0178796.ref023], [@pone.0178796.ref030]--[@pone.0178796.ref032]\]. In our study EDTA did not inhibit the *in vitro* binding of cysC to immobilized megalin or cubilin. This is consistent with the observation that FITC labeled cysC binding to purified rat brush-border membrane using a rapid filtration technique was reduced only 40% when increasing the EDTA concentration in the incubation buffer to 20 mM suggesting some Ca^2+^ independent binding of cysC to megalin \[[@pone.0178796.ref031]\]. Ca^2+^ independent binding to megalin has also been demonstrated for insulin \[[@pone.0178796.ref033]\].

A previous study of cisplatin induced AKI in rats \[[@pone.0178796.ref034]\] showed no changed in tissue content of cysC suggesting that this was due to a combination of decreased uptake and catabolism of cysC. In contrast, we observed a decrease in tubular cysC labeling suggesting decreased tubular uptake and no evidence of intracellular cysC accumulation. This suggests that the increase in U-CysC following I/R injury might be due to dysfunction of the endocytic process with no apparent change in megalin expression. We observed specific tubular damage with loss of cell polarity and adhesion to the tubular basal membrane and interstitial hyper-cellularity in our I/R rats. The PT cells in the segments S1 and S3 are very susceptible to I/R damage \[[@pone.0178796.ref035]\] due to their high metabolic rate and demand for ample oxygen resources which could explain these observations.

Several experimental studies using animal models of AKI \[[@pone.0178796.ref036]\], CKD \[[@pone.0178796.ref037]\], hypertensive \[[@pone.0178796.ref038]\] and diabetic nephropathy \[[@pone.0178796.ref039]\] have reported changes in megalin expression in the proximal tubule; however, few studies have addressed the endocytic function of megalin in kidney injury. When feeding rats large doses of L-Lysine Thelle et al \[[@pone.0178796.ref040]\] induced tubular proteinuria and abolished megalin dependent endocytosis in the PT. In their study, megalin and cubilin expression in the tubular brush border membrane was preserved. They concluded that the observed tubular proteinuria was, at least in part, due to dysfunctional vesicle trafficking--not just inhibition of ligand binding to megalin. We found cysC endocytosis to be dependent on binding to megalin; however, decreased megalin expression does not appear to be the major cause of increased U-cysC excretion in I/R injury. Thus, the urinary excretion of cysC may be a marker of megalin dependent endocytic function in the proximal tubule. Whether this will provide important pathophysiological information in acute or chronic kidney injury remains to be established.

This work was conducted with financial support from The Danish Medical Research Council, The Novo-Nordisk Foundation, The Lundbeck Foundation, and Fonden til Lægevidenskabens Fremme. No potential conflict of interest, relevant to this article, was reported. Hanne Sidelmann, Inger Blenker Kristoffersen, Pia Kamuk Nielsen, and Helle Salling Gittins, are gratefully acknowledged for excellent technical assistance, as is Anne-Marie Bundsgaard and Professor Anders Nykjaer (Department of Biomedicine, Aarhus University) for their assistance concerning the surface plasmon resonance analysis experiments.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: **Conceptualization:** DJ R. Nielsen HB EIC.**Data curation:** DJ HB CKL R. Nielsen EIC MLVK.**Formal analysis:** DJ HB.**Funding acquisition:** DJ HB EIC R. Nielsen.**Investigation:** DJ HB CKL MLVK KW.**Methodology:** DJ R. Nielsen HB EIC CKL MLVK R. Nørregaard.**Project administration:** DJ HB EIC R. Nielsen R. Nørregaard CKL MLVK.**Resources:** R. Nørregaard EIC R. Nielsen KW HB MLVK CKL HB.**Software:** DJ.**Supervision:** HB R. Nielsen R. Nørregaard EIC.**Validation:** DJ HB R. Nielsen EIC.**Visualization:** DJ HB.**Writing -- original draft:** DJ HB.**Writing -- review & editing:** DJ HB.
